FDA hearing: psychedelics launch needs balanced regulation without limiting access

The article discusses an FDA hearing regarding the regulation of psychedelic substances. The main focus is on the need to find a balanced approach to regulation that would enable the development and access to these substances without unnecessary restrictions. The discussion centers on how to create a regulatory framework that would support research and clinical applications of psychedelics while maintaining patient safety. The hearing emphasizes the importance of dialogue between regulatory agencies, researchers, and the pharmaceutical industry. The goal is to achieve regulation that does not hinder innovation and access to potential therapeutic options.